Research to improve our understanding of Duchenne muscular dystrophy (DMD), and the development of new therapies, has previously relied on mouse models. However, physiological differences between the two species has limited how successfully findings in mice can be applied to humans. A newly developed rabbit model, created through the use of CRISPR/Cas-9 genome editing, exhibits greater clinical similarity to human patients than the mouse models currently in use, with huge potential to advance DMD research.